FGF21 mutant protein and its fusion protein

By mutation of the FGF21 protein amino acid site and fusion with the GDF-15 protein, combining the Fc fragment, the problems of short half-life and unstable aggregation of FGF21 protein were solved, and significant metabolic regulation effect was achieved, suitable for the treatment of a variety of Metabolic-related diseases.

CN113366024BActive Publication Date: 2024-11-05SHANGHAI HANSOH BIOMEDICAL CO LTD +1
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202180001894.4
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Priority Date
2021-01-05
Filing Date
2021-01-08
Publication Date
2024-11-05
Estimated Expiration
2041-01-08

AI Technical Summary

Technical Problem

As a drug for treating diabetes and obesity, FGF21 is easily hydrolyzed by proteases as a small molecule protein, with a short half-life, making it difficult to ensure the time of effective drugs, and its own aggregation is unstable, resulting in the application of the preparation facing tolerance and stability challenges. .

Method used

By mutation of the amino acid site of the FGF21 protein, a variety of mutants were prepared and linked to the GDF-15 protein through a conjunctive protein, especially a fusion protein containing Fc fragments, to improve the half-life and stability of the protein and enhance the Its metabolic activity and therapeutic effect in the body.

Benefits of technology

It has achieved significant induction of glucose uptake by FGF21 protein, promotes phosphorylation of ERK1/2 protein, and regulates blood sugar and body weight. It has significant and long-lasting effects on lowering blood sugar and body weight, which is significantly better than traditional FGF21 mutants and has good metabolic regulation effect. Suitable for the treatment of diseases such as diabetes, obesity, dyslipidemia and metabolic syndrome.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure GSB0000204886750000051
    Figure GSB0000204886750000051
  • Figure GSB0000204886750000101
    Figure GSB0000204886750000101
  • Figure GSB0000204886750000111
    Figure GSB0000204886750000111
Patent Text Reader

Abstract

The present invention provides an FGF21 mutant protein, a fusion protein comprising an FGF21 protein or its mutant protein and Fc, GDF-15 or its mutant protein, and a method for using the FGF21 mutant protein, the fusion protein comprising the FGF21 mutant protein and a pharmaceutical composition thereof for treating diabetes, obesity, dyslipidemia, metabolic syndrome, non-alcoholic fatty liver disease or non-alcoholic steatohepatitis and other related diseases.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the field of biomedicine, and specifically relates to a mutant protein of FGF21, a fusion protein of the mutant protein of FGF21 and Fc and growth differentiation factor-15 (GDF15). Background Art

[0002] Fibroblast growth factor 21 (FGF21) is a polypeptide consisting of 209 amino acids (SEQ ID NO: 152), and its amino acid sequence has about 75% homology with mouse FGF21. The N-terminus of FGF21 contains a signal peptide consisting of 28 amino acids, so mature FGF21 consists of 181 amino acids (SEQ ID NO: 154). Mature FGF21 has a natural human FGF21 isoform or allelic form in which Leu replaces Pro at position 146 of SEQ ID NO: 154 herein. FGF21 is mainly expressed in the liver and pancreas, and is also present in adipose and muscle tissues. Through the mediation of FGFR and the assistance of transmembrane protein βKlotho (KLB), FGF21 can induce multiple signaling pathways and functional activities in the liver, pancreas and adipose tissue, thereby achieving the physiological functions of regulating glucose and lipid metabolism and protecting pancreatic β cells. FGF21 regulates glucose uptake by adipocytes by activating non-insulin-dependent glucose absorption. In addition, studies have also shown that FGF21 can reduce body weight and body fat in a dose-dependent manner. For example, when FGF21 was administered to diabetic rhesus monkeys, it was found that their fasting plasma glucose, triglycerides, and glucagon levels were significantly reduced. At the same time, it was found in FGF21 transgenic mice that their white adipose tissue lipase expression increased, and plasma β-hydroxybutyrate and free fatty acid levels increased. This means that FGF21 may regulate lipid metabolism by promoting lipolysis and ketosis. In pancreatic islet cells and INS-1E cells, FGF21 can inhibit glucose-mediated glucagon release, stimulate insulin production, and prevent islet cell apoptosis, thereby improving pancreatic cell function. In addition, FGF21 can also activate exocrine pancreatic cell and hepatocyte signaling pathways and inhibit liver glycogen output.

[0003] As a member of the FGF gene family, most FGFs have a broad spectrum of mitogenic ability. However, the results of the study show that FGF21 has neither the ability to promote cell proliferation nor the ability to antagonize the functions of other members of the FGF family. Experiments have shown that FGF21 transgenic mice (the amount of FGF21 in the body is about 150 times that of normal mice) have no abnormal conditions such as tumors and tissue hyperplasia in their bodies throughout their life cycle. At the same time, its metabolic regulation is related to the body's metabolic level, and the regulation only works when the metabolism is abnormal. Even if the pharmacological dose of FGF21 is exceeded, hypoglycemia will not occur. The main drugs for the treatment of diabetes on the market (insulin, thiazolidinediones, etc.) are prone to side effects when the dose is inappropriate, such as hypoglycemia caused by large doses of insulin, liver damage and edema caused by thiazolidinediones, which were not found in animal experiments treated with FGF21. This is enough to prove that FGF21 is an ideal drug for the treatment of diabetes and obesity.

[0004] The physiological functions of FGF21 in controlling blood sugar and reducing body weight have brought hope for the treatment of related diseases. However, as a small molecule protein, wild-type FGF21 is easily hydrolyzed by proteases and can also be filtered through the glomeruli. Its half-life is only 0.5-2h, which makes it difficult to ensure the effective drug action time. Faced with this difficulty, the pharmaceutical industry has increased the half-life of FGF21 by performing site-directed mutations of amino acids at the enzyme cleavage site, preparing long-acting fusion proteins, or connecting polyethylene glycol to the polypeptide backbone. In addition, a major challenge in the development of FGF21 as a protein preparation also comes from the instability caused by its own aggregation. The ideal effect of the target therapeutic protein is to increase tolerance to proteolysis and reduce protein aggregation, thereby enhancing the half-life and stability of the FGF21 protein preparation and achieving low-frequency dosing for patients.

[0005] Some mutants based on the human wild-type FGF21 polypeptide sequence have been described in WO2009 / 149171 and WO2017 / 074117.

[0006] Growth differentiation factor 15 (GDF-15) is a branch member of the TGF superfamily. It is also known as macrophage inhibitory cytokine 1 (MIC1), placental bone morphogenetic factor (PLAB), placental transforming growth factor β (PTGFB), prostate-derived factor (PDF) and nonsteroidal anti-inflammatory drug activated gene (NAG-1). The mature GDF15 peptide shares low homology with its family members.

[0007] GDF-15 has been reported to play an important role in regulating body weight. GDF-15 is usually only active when the body experiences acute or long-term stress, including exposure to toxic substances that damage tissues, such as chemotherapy drugs, or during chronic diseases such as obesity or cancer. Therefore, the GDF15 pathway is expected to allow people to develop potential drugs to treat diseases related to excessive obesity and underweight. Based on the relevant research results, researchers are developing GDF-15 or its variant proteins as drugs to treat obesity. Obesity is a growing epidemic that is estimated to affect 78 million adults in the United States. Summary of the invention

[0008] One embodiment of the present invention is a polypeptide based on the wild-type human FGF21 sequence (SEQ ID NO: 154), wherein:

[0009] (1) Leu at position 98 from the N-terminus of the wild-type FGF21 protein was replaced by Arg;

[0010] (2) Gly at position 170 from the N-terminus of the wild-type FGF21 protein was replaced by Thr;

[0011] (3) Ser at position 172 from the N-terminus of the wild-type FGF21 protein was replaced by Leu;

[0012] (4) Arg at position 175 from the N-terminus of the wild-type FGF21 protein is replaced by one of Phe, Glu, Trp, Leu, Tyr, or Ile;

[0013] and (5) Ala at position 180 from the N-terminus of the wild-type FGF21 protein was replaced by Glu;

[0014] In yet another embodiment:

[0015] (1) Leu at position 98 from the N-terminus of the wild-type FGF21 protein was replaced by Arg;

[0016] (2) Ser at position 163 from the N-terminus of the wild-type FGF21 protein is replaced by one of Phe, Trp, Tyr, Leu, Gln or Thr;

[0017] (3) Gly at position 170 from the N-terminus of the wild-type FGF21 protein was replaced by Thr;

[0018] (4) Ser at position 172 from the N-terminus of the wild-type FGF21 protein was replaced by Leu;

[0019] and (5) Ala at position 180 from the N-terminus of the wild-type FGF21 protein was replaced by Glu;

[0020] A further preferred embodiment of the present invention, wherein:

[0021] (1) Leu at position 98 from the N-terminus of the wild-type FGF21 protein was replaced by Arg;

[0022] (2) Ser at position 163 from the N-terminus of the wild-type FGF21 protein is replaced by one of Phe, Trp, Tyr, Leu, Glu Ile, Asp or His;

[0023] (3) Gly at position 170 from the N-terminus of the wild-type FGF21 protein was replaced by Thr;

[0024] (4) Ser at position 172 from the N-terminus of the wild-type FGF21 protein was replaced by Leu;

[0025] (5) Arg at position 175 from the N-terminus of the wild-type FGF21 protein is replaced by one of Phe, Glu, Trp, Leu, Tyr, or Ile;

[0026] (6) Ala at position 180 from the N-terminus of the wild-type FGF21 protein was replaced by Glu;

[0027] Another preferred embodiment of the present invention, wherein:

[0028] (1) Leu at position 98 from the N-terminus of the wild-type FGF21 protein was replaced by Arg;

[0029] (2) Pro at position 171 from the N-terminus of the wild-type FGF21 protein was replaced by Gly;

[0030] (3) Arg at position 175 from the N-terminus of the wild-type FGF21 protein is replaced by one of Phe, Glu, Trp, Leu, Tyr, or Ile;

[0031] (4) Ala at position 180 from the N-terminus of the wild-type FGF21 protein was replaced by Glu;

[0032] In another preferred embodiment of the present invention:

[0033] (1) Leu at position 98 from the N-terminus of the wild-type FGF21 protein was replaced by Arg;

[0034] (2) Ser at position 163 from the N-terminus of the wild-type FGF21 protein is replaced by one of Phe, Trp, Tyr, Leu, Gln or Thr;

[0035] (3) Pro at position 171 from the N-terminus of the wild-type FGF21 protein was replaced by Gly;

[0036] (4) Ala at position 180 from the N-terminus of the wild-type FGF21 protein was replaced by Glu;

[0037] In another preferred embodiment of the present invention:

[0038] (1) Leu at position 98 from the N-terminus of the wild-type FGF21 protein was replaced by Arg;

[0039] (2) Ser at position 163 from the N-terminus of the wild-type FGF21 protein is replaced by one of Phe, Trp, Tyr, Leu, Glu, Ile, Asp or His;

[0040] (3) Pro at position 171 from the N-terminus of the wild-type FGF21 protein was replaced by Gly;

[0041] (4) Arg at position 175 from the N-terminus of the wild-type FGF21 protein is replaced by one of Phe, Glu, Trp, Leu, Tyr, or Ile;

[0042] (5) Ala at position 180 from the N-terminus of the wild-type FGF21 protein was replaced by Glu;

[0043] In another preferred embodiment of the present invention:

[0044] (1) Leu at position 98 from the N-terminus of the wild-type F1.GF21 protein was replaced by Arg;

[0045] (2) Gly-Pro-Ser at positions 170-172 from the N-terminus of the wild-type FGF21 protein was replaced by Thr-Gly-Leu;

[0046] (3) Arg at position 175 from the N-terminus of the wild-type FGF21 protein is replaced by one of Phe, Glu, Trp, Leu, Tyr, or Ile;

[0047] (4) Ala at position 180 from the N-terminus of the wild-type FGF21 protein was replaced by Glu;

[0048] In another preferred embodiment of the present invention:

[0049] (1) Leu at position 98 from the N-terminus of the wild-type F1.GF21 protein was replaced by Arg;

[0050] (2) Ser at position 163 from the N-terminus of the wild-type FGF21 protein is replaced by one of Phe, Trp, Tyr, Leu, Gln or Thr;

[0051] (3) Gly-Pro-Ser at positions 170-172 from the N-terminus of the wild-type FGF21 protein was replaced by Thr-Gly-Leu;

[0052] (4) Ala at position 180 from the N-terminus of the wild-type FGF21 protein was replaced by Glu;

[0053] In another preferred embodiment of the present invention:

[0054] (1) Leu at position 98 from the N-terminus of the wild-type FGF21 protein was replaced by Arg;

[0055] (2) Ser at position 163 from the N-terminus of the wild-type FGF21 protein is replaced by one of Phe, Trp, Tyr, Leu, Glu, Ile, Asp or His;

[0056] (3) Gly-Pro-Ser at positions 170-172 from the N-terminus of the wild-type FGF21 protein was replaced by Thr-Gly-Leu;

[0057] (4) Arg at position 175 from the N-terminus of the wild-type FGF21 protein is replaced by one of Phe, Glu, Trp, Leu, Tyr, or Ile;

[0058] (5) Ala at position 180 from the N-terminus of the wild-type FGF21 protein was replaced by Glu;

[0059] In another preferred embodiment of the present invention:

[0060] (1) Leu at position 98 from the N-terminus of the wild-type FGF21 protein was replaced by Arg;

[0061] (2) Pro at position 146 from the N-terminus of the wild-type FGF21 protein was replaced by Leu;

[0062] (3) Leu at position 166 from the N-terminus of the wild-type FGF21 protein was replaced by Phe;

[0063] (4) Pro at position 171 from the N-terminus of the wild-type FGF21 protein was replaced by Gly;

[0064] (5) Arg at position 175 from the N-terminus of the wild-type FGF21 protein was replaced by Trp;

[0065] (6) Ala at position 180 from the N-terminus of the wild-type FGF21 protein was replaced by Glu;

[0066] In another preferred embodiment of the present invention:

[0067] (1) Leu at position 98 from the N-terminus of the wild-type FGF21 protein was replaced by Arg;

[0068] (2) Pro at position 146 from the N-terminus of the wild-type FGF21 protein was replaced by Leu;

[0069] (3) Leu at position 166 from the N-terminus of the wild-type FGF21 protein was replaced by Phe;

[0070] (4) Gly-Pro-Ser at positions 170-172 from the N-terminus of the wild-type FGF21 protein was replaced by Thr-Gly-Leu;

[0071] (5) Arg at position 175 from the N-terminus of the wild-type FGF21 protein was replaced by Trp;

[0072] (6) Ala at position 180 from the N-terminus of the wild-type FGF21 protein was replaced by Glu;

[0073] In another preferred embodiment of the present invention:

[0074] (1) Leu at position 98 from the N-terminus of the wild-type FGF21 protein was replaced by Arg;

[0075] (2) Pro at position 146 from the N-terminus of the wild-type FGF21 protein was replaced by Leu;

[0076] (3) Ser at position 163 from the N-terminus of the wild-type FGF21 protein is replaced by one of Phe, Trp, Asp, Leu, Glu or Ile;

[0077] (4) Leu at position 166 from the N-terminus of the wild-type FGF21 protein was replaced by Phe;

[0078] (5) Pro at position 171 from the N-terminus of the wild-type FGF21 protein was replaced by Gly;

[0079] (6) Arg at position 175 from the N-terminus of the wild-type FGF21 protein was replaced by Trp;

[0080] (7) Ala at position 180 from the N-terminus of the wild-type FGF21 protein was replaced by Glu;

[0081] In another preferred embodiment of the present invention:

[0082] (1) Leu at position 98 from the N-terminus of the wild-type FGF21 protein was replaced by Arg;

[0083] (2) Pro at position 146 from the N-terminus of the wild-type FGF21 protein was replaced by Leu;

[0084] (3) Ser at position 163 from the N-terminus of the wild-type FGF21 protein is substituted with one of Phe, Trp, His, Leu, Glu or Ile;

[0085] (4) Leu at position 166 from the N-terminus of the wild-type FGF21 protein was replaced by Phe;

[0086] (5) Gly-Pro-Ser at positions 170-172 from the N-terminus of the wild-type FGF21 protein was replaced by Thr-Gly-Leu;

[0087] (6) Arg at position 175 from the N-terminus of the wild-type FGF21 protein was replaced by Trp;

[0088] (7) Ala at position 180 from the N-terminus of the wild-type FGF21 protein was replaced by Glu;

[0089] Another preferred embodiment of the present invention, wherein the FGF21 variant protein and the GDF-15 protein are linked via a linker protein.

[0090] Another preferred embodiment of the present invention is that the FGF21 variant protein is connected to the GDF-15 protein via a connecting protein, and the connecting protein contains the Fc fragment of immunoglobulin.

[0091] The present invention provides a FGF21 protein or a variant thereof, the general formula of which is as follows:

[0092]

[0093] in:

[0094] X 146 is Pro or Leu; X 163 Selected from Asp, Ser, Phe, Glu, His, Trp, Tyr, Leu, Gln, Ile or Thr;

[0095] X 166 is Leu or Phe; X 170 is Gly or Thr; X 171 Pro or Gly; X 172 Ser or Leu;

[0096] X 175 Selected from Arg, Phe, Glu, Trp, Leu, Tyr or Ile.

[0097] One embodiment of the present invention is the FGF21 protein or its variant described in general formula (I), wherein:

[0098] X 146is Pro or Leu; X 163 Selected from Asp, Ser, Phe, Glu, His, Trp, Tyr, Leu, Gln, Ile or Thr;

[0099] X 166 is Leu or Phe; X 170 Gly;X 171 Pro or Gly; X 172 Ser; X 175 Selected from Arg, Phe, Glu, Trp, Leu, Tyr or Ile.

[0100] One embodiment of the present invention is the FGF21 protein or its variant described in general formula (I), wherein:

[0101] X 146 For Pro;X 163 is selected from Ser, Phe, Glu, His, Trp, Tyr, Leu, Gln or Thr; X 166 Leu;X 170 Gly;X 171 Gly;X 172 Ser; X 175 Selected from Arg, Phe, Glu, Trp, Leu, Tyr or Ile.

[0102] One embodiment of the present invention is the FGF21 protein or its variant described in general formula (I), wherein:

[0103] X 146 Selected from Pro or Leu; X 163 is selected from Phe, Ile, Ser or Trp; X 166 Selected from Leu or Phe; X 170 Gly;X 171 Gly;X 172 Ser; X 175 Selected from Arg or Trp.

[0104] One embodiment of the present invention is the FGF21 protein or its variant described in general formula (I), wherein:

[0105] X 146 Selected from Pro or Leu; X 163 Trp;X 166 Leu;X 170 Gly;X 171 Gly;X 172 Ser; X 175One embodiment of the present invention is the FGF21 protein or its variant described in general formula (I), wherein,

[0106] X 146 Leu;X 163 is selected from Asp, Ser, Phe, Glu, Trp, Leu or Ile; X 166 Phe;X 170 Gly;X 171 Pro or Gly; X 172 Ser; X 175 Selected from Arg, Phe, Glu, Trp, Leu, Tyr or Ile.

[0107] One embodiment of the present invention is the FGF21 protein or its variant described in general formula (I), wherein X 146 Leu;X 163 is selected from Asp, Ser, Phe, Glu, Trp, Leu or Ile; X 166 Phe;X 170 Gly;X 171 Pro or Gly; X 172 Ser; X 175 Selected from Trp.

[0108] Another embodiment of the present invention is the FGF21 protein or its variant described in general formula (I), wherein X 146 is Pro or Leu; X 163 is Ser, Phe, Glu, His, Trp, Tyr, Leu, Gln, Ile or Thr; X 166 is Leu or Phe; X 170 is Thr;X 171 Pro or Gly; X 172 Leu;X 175 The amino acid at position is Arg, Phe, Glu, Trp, Leu, Tyr or Ile.

[0109] Another embodiment of the present invention is the FGF21 protein or its variant described in general formula (I), wherein X 146 For Pro;X 163 is Ser, Phe, Glu, His, Trp, Tyr, Leu, Gln or Thr; X 166 Leu;X 170 is Thr;X 171 Pro or Gly; X 172 Leu;X 175The amino acid at position is Arg, Phe, Glu, Trp, Leu, Tyr or Ile.

[0110] Another embodiment of the present invention is the FGF21 protein or its variant described in general formula (I), wherein:

[0111] X 146 For Pro;X 163 is selected from Ser, Phe, Glu, His, Trp, Tyr, Leu, Gln or Thr; X 166 Leu;X 170 is Thr;X 171 For Pro;X 172 Leu;X 175 Selected from Arg, Phe, Glu, Trp, Leu, Tyr or Ile.

[0112] Another embodiment of the present invention is the FGF21 protein or its variant described in general formula (I), wherein:

[0113] X 146 Leu;X 163 is Ser, Phe, Glu, His, Trp, Leu or Ile; X 166 Phe;X 170 is Thr;X 171 For Pro;X 172 Leu;X 175 The amino acid at position is Arg, Phe, Glu, Trp, Leu, Tyr or Ile.

[0114] Another embodiment of the present invention is the FGF21 protein or its variant described in general formula (I), wherein X 146 Leu;X 163 is Ser, Phe, Glu, His, Trp, Leu or Ile; X 166 Phe;X 170 is Thr;X 171 Gly;X 172 Leu;X 175 The amino acid at position is Trp.

[0115] Another embodiment of the present invention is the FGF21 protein described in general formula (I) or a variant thereof, selected from the sequence SEQ ID NO: 1-144 or SEQ ID NO: 155-171.

[0116] The present invention also relates to a fusion protein, which contains the FGF21 protein or its variant described in general formula (I), and its general formula is as follows:

[0117] F1-F2-F3 (II)

[0118] in:

[0119] F1 is FGF21 protein or its variant; F2 is connexin; F3 is GDF15 protein or its variant.

[0120] Another embodiment of the present invention is a fusion protein of general formula (II), wherein the connexin of F2 is of general formula:

[0121] F4F5(GGGGS) m F5(GGGGS) n (III)

[0122] in:

[0123] F4 is SEQ ID NO: 145; F5 is the Fc fragment of an immunoglobulin; m=1-20; and n=1-8.

[0124] Another embodiment of the present invention is the fusion protein of formula (II), wherein the connecting protein of F2 is of formula (III), wherein F5 is SEQ ID NO: 146.

[0125] Another embodiment of the present invention is the fusion protein of general formula (II), wherein the connexin of F2 is of general formula (III), wherein m=10.

[0126] Another embodiment of the present invention is the fusion protein of formula (II), wherein the connexin of F2 is of formula (III), wherein n=4.

[0127] Another embodiment of the present invention is a fusion protein of general formula (II), wherein the connexin of F2 is of general formula (III), and the specific sequence is SEQ ID NO: 147.

[0128] Another embodiment of the present invention is the fusion protein of general formula (II), wherein the sequence of the GDF15 protein of F3 or its variant is SEQ ID NO: 148.

[0129] Another embodiment of the present invention is the fusion protein of general formula (II), and the specific sequences are SEQ ID NOs: 149 and 150.

[0130] The present invention also relates to a polynucleotide encoding the FGF21 protein described in general formula (I) or its variant or the fusion protein described in general formula (II).

[0131] The present invention also relates to an expression vector comprising the polynucleotide as described above.

[0132] In addition, the present invention also relates to a host cell, which is introduced into or contains the expression vector as described above, wherein the host cell is a bacterium, preferably Escherichia coli; or the host cell is a yeast, preferably Pichia pastoris; or the host cell is a mammalian cell, preferably a CHO cell or HEK293 cell.

[0133] The present invention also relates to a method for producing protein, comprising the steps of:

[0134] 1) Cultivating the host cell as described above;

[0135] 2) Isolation of proteins from culture;

[0136] 3) and purifying the protein.

[0137] The present invention further comprises a pharmaceutical composition, which contains the FGF21 protein or its variant described in general formula (I) or the fusion protein described in general formula (II) and a pharmaceutically acceptable excipient, diluent or carrier.

[0138] The present invention also relates to the use of the FGF21 protein or its variant, fusion protein or the pharmaceutical composition as described above in the preparation of drugs, which are used to treat or prevent related diseases such as diabetes, obesity, dyslipidemia, metabolic syndrome, non-alcoholic fatty liver or non-alcoholic steatohepatitis.

[0139] The FGF21 mutant protein provided by the present invention has the effects of significantly inducing glucose uptake, promoting the phosphorylation of ERK1 / 2 protein, and regulating blood sugar and body weight. The fusion protein of the FGF21 mutant and Fc and GDF-15 protein provided by the present invention has the advantages that are significantly superior to FGF21 and the known FGF21 mutants disclosed in the art, and can significantly and lastingly reduce blood sugar and body weight, and has good metabolic regulation effect and in vivo metabolic activity. These characteristics are beneficial for the preparation and formulation of therapeutic proteins, and have potential therapeutic effects on related diseases such as diabetes, obesity, dyslipidemia, metabolic syndrome, non-alcoholic fatty liver or non-alcoholic fatty hepatitis.

[0140] Detailed description of the invention

[0141] Unless stated otherwise, the terms used in the specification and claims have the following meanings.

[0142] The amino acid positions in the FGF21 mutants of the present invention are changed based on the amino acid positions in the mature human wild-type FGF21 (SEQ ID NO: 154) polypeptide.

[0143] The amino acid sequences of the present invention contain the standard one-letter or three-letter codes for the twenty amino acids.

[0144] The term "FGF21 polypeptide" refers to a naturally occurring wild-type polypeptide expressed in humans, including a full-length form consisting of SEQ ID NO: 152 and encoded by SEQ ID NO: 151 and a mature form consisting of SEQ ID NO: 154 and encoded by SEQ ID NO: 153.

[0145] The term "FGF21 mutant" refers to a modified FGF21 polypeptide based on the naturally occurring FGF21 amino acid sequence (SEQ ID NO: 154). Such modifications include, but are not limited to, substitutions of one or more amino acids, including, but not limited to, the protease-resistant FGF21 mutants, the aggregation-reduced FGF21 mutants, and the FGF21 combination mutants described herein.

[0146] The term "conservative amino acid mutation" refers to a substitution of a natural amino acid residue such that the polarity or charge of the amino acid residue at that position is barely affected.

[0147] Amino acids can be divided into the following categories based on the properties of their side chains:

[0148] (1) Hydrophobicity: Ala, Ile, Leu, Met, Phe, Pro and Trp;

[0149] (2) Neutral hydrophilicity: Cys, Ser or Thr;

[0150] (3) Acidic: Asp, Glu;

[0151] (4) Basic: Arg, Asn, Gln, His or Lys.

[0152] Conservative substitutions involve replacing a member of one of these classes with a member of another class; nonconservative substitutions involve replacing a member of one of these classes with a member of another class.

[0153] The term "dyslipidemia" refers to a disorder of lipoprotein metabolism, including an overproduction or underproduction of lipoproteins. It can be manifested as an increase in the concentrations of total cholesterol, low-density lipoprotein cholesterol and triglycerides and / or a decrease in the concentration of high-density lipoprotein cholesterol in the blood.

[0154] The term "patient" refers to a mammal, preferably a human.

[0155] The terms "treat," ...

[0156] The term "Fc fragment" refers to the constant region of the heavy chain of an immunoglobulin.

[0157] The term "vector" refers to any molecule (eg, nucleic acid, plasmid or virus) used to transfer coding information to a host cell.

[0158] The term "expression vector" refers to a vector suitable for host cell transformation and containing a nucleic acid sequence that directs and / or controls the expression of an inserted heterologous nucleic acid sequence, including but not limited to processes such as transcription, translation, and RNA splicing.

[0159] The term "host cell" is used to refer to a cell that is transformed or capable of being transformed by a nucleic acid sequence and then capable of expressing a selected target gene. The term includes the progeny of a parent cell, whether or not the progeny is identical to the original parent in morphology or genetic composition, with the selected gene predominantly present. DETAILED DESCRIPTION

[0160] In order to illustrate the present invention in more detail, this specification provides the following specific implementation schemes, but the solutions of the present invention are not limited thereto.

[0161] 1. Main experimental reagents:

[0162] name brand Part Number NI Sepharose excel GE 17-3712-01 NaOH Shanghai Test 10019718 Imidazole Shanghai Test 10000218 PBS The prosperity of the country BF-0012 75% ethanol Shanghai Test 801769610 Eshmuno A MERCK 1.25161.0001 Acetic acid Shanghai Test 10000218 Sodium acetate (trihydrate) Shanghai Test 10018718

[0163] 2. Main experimental instruments:

[0164] name brand model Protein Purification Instrument GE AKTA-Pure150 Micro-volume spectrophotometer Hangzhou Aosheng Nano-300 Multifunctional ELISA reader Thermo Lux

[0165] Example 1 Preparation of Protein No. 1

[0166] The target protein was expressed using the ExpiCHO system (Thermo Fisher #A29133).

[0167] Specifically, a DNA sequence encoding a numbered protein sequence (SEQ ID NO: 1) with a His tag at the C-terminus was cloned into a pCDNA3.1 vector, and after sequencing, a plasmid expressing the target protein was confirmed. The plasmid was transfected into ExpiCHO-S cells using ExpiFectamine reagent, and the cells were cultured in 100 ml of ExpiCHO medium for 7 days, and the supernatant was harvested; the fermentation broth was clarified by centrifugal filtration or deep filtration.

[0168] The method for preparing EQ buffer (PBS, pH 7.4) is to take a bag of PBS phosphate buffer powder, dissolve the powder in 2000 ml of ultrapure water, and filter it with a 0.22 μm filter membrane for later use.

[0169] The method for preparing Elution buffer (500 mM imidazole, pH 7.4) is as follows: weigh 34 g of imidazole and add 450 ml of EQ buffer, adjust the pH to 7.4, make up to 500 ml, and filter through a 0.22 μm filter membrane for later use.

[0170] The harvested supernatant was purified by AKTA Pure instrument. First, the instrument was balanced with EQ buffer until the pH and conductivity of the outflowing liquid were consistent with EQ buffer; then the sample was collected with Elution buffer. 1.3 Experimental results:

[0171] The concentration of protein No. 1 was determined by ultraviolet spectrophotometry to be 847 mg / L and the purity was 96%.

[0172] Example 2 Preparation of Protein Nos. 2-144 and 155-171

[0173] The proteins No. 2-144 and 155-171 were prepared by the method of Example 1, and the concentration and purity of the proteins No. 2-144 and 155-171 were determined by ultraviolet spectrophotometry, as shown in the following table:

[0174]

[0175]

[0176]

[0177]

[0178]

[0179]

[0180] Example 3 Preparation of Protein Nos. 149 and 150

[0181] The fusion protein was expressed using the ExpiCHO system (Thermo Fisher #A29133).

[0182] Specifically, the DNA sequences encoding the protein sequence No. 149 (SEQ ID NO: 149) and the protein sequence No. 150 (SEQ ID NO: 150) were cloned into the pCDNA3.1 vector, and the plasmid expressing the fusion protein was confirmed by sequencing. The plasmid was transfected into ExpiCHO-S cells using ExpiFectamine reagent, and the cells were cultured in 100 ml of ExpiCHO medium for 7 days, and the supernatant was harvested. The fermentation broth was clarified by centrifugal filtration or deep filtration.

[0183] The method for preparing EQ buffer (PBS, pH 7.4) is to take a bag of PBS phosphate buffer powder, dissolve the powder in 2000 ml of ultrapure water, and filter it with a 0.22 μm filter membrane for later use.

[0184] The method for preparing Elution buffer (50 mM HAc-NaAc, pH 3.5) is as follows: weigh 1.91 g of sodium acetate trihydrate, add glacial acetic acid to adjust the pH to 3.5, make up to 1000 ml, and filter through a 0.22 μm filter membrane for later use.

[0185] The harvested supernatant was purified by the AKTA Pure instrument. The instrument was first balanced with EQ buffer until the pH and conductivity of the outflowing liquid were consistent with the EQ buffer. The sample was then collected with Elution buffer.

[0186] Experimental results:

[0187] The protein concentration of No. 149 was 965 mg / L and the purity was 92% as determined by UV spectrophotometry; the protein concentration of No. 150 was 893 mg / L and the purity was 87%.

[0188] Example 4 Study on the glucose uptake function induced by FGF21 mutants

[0189] To evaluate the regulatory effect of FGF21 protein mutants on glucose uptake levels. Glucose transporter 1 (GLUT1) is expressed on the surface of mature adipocytes differentiated from 3T3-L1 mouse embryonic fibroblasts. FGF21 protein regulates the glucose uptake level of adipocytes by regulating the expression level of GLUT1.

[0190] The cultured 3T3-L1 (Nanjing Kebai, cat#: CBP60758) mouse embryonic fibroblasts were digested with trypsin (Gibco, cat#: 25200-056) to prepare a single cell suspension and adjust the cell density to 1x10 6 / mL, inoculated into T75 culture flasks, and cultured overnight in a 37°C, 5% carbon dioxide incubator. The original culture medium was aspirated and an induction medium was added, i.e., 2 μg / ml human insulin (Sinobiologics, cat#: 11038-HNAY) solution, 1 μM dexamethasone (Sigma, cat#: D4902-25MG) and 0.5 mM 3-isobutyl-1-methylxanthine (IBMX) (Sigma, cat#: I7018-100MG) were added to a complete medium containing DMEM (gibco, cat#: 1009141C) with 10% fetal bovine serum (gibco, cat#: 1009141C), and 3T3-L1 cells were induced and cultured for 3 days. The number and size of intracellular fat particles were observed under a microscope to differentiate them into adipocytes, and then the differentiation medium was replaced with a complete medium containing only 2 μg / ml human insulin.

[0191] The induced differentiated mature adipocytes were digested and single cell suspension was prepared. The cell density was adjusted to 1x10 6 / mL, 100uL / well, inoculated in a 96-well plate (Corning, cat#: 3610), wait for the cells to adhere to the wall, add the protein to be tested diluted with DMEM basal medium to a final concentration of 5000nM in the experimental group, 100uL / well added to the plate, and add the same volume of DMEM basal medium to the control group, incubated at 37°C, 5% carbon dioxide overnight. The next day, the cells were starved in DMEM basal medium for 2 hours, then 100uM 2-NBDG was added, incubated at 37°C for 1 hour, washed twice with pH7.4 PBS solution, digested with trypsin, prepared single cell suspension, and transferred to a V-bottom 96-well plate. The intracellular 2-NBDG signal was detected using a ZE5 flow cytometer, and the glucose uptake rate was calculated using MFI. The calculation formula: Glucose uptake rate % = (experimental group MFI-control group MFI) / control group MFI*100%.

[0192] The experimental results are as follows:

[0193] Table 1 Regulatory effects of FGF21 protein mutants on glucose uptake levels

[0194]

[0195]

[0196] The experimental results showed that the FGF21 mutant induced adipocytes to take up the glucose analog 2-NBDG at a concentration of 5000nM, with good induction efficiency.

[0197] Example 5 Study on the cellular function of FGF21 mutants inducing ERK1 / 2 protein phosphorylation

[0198] FGF21 protein regulates the phosphorylation level of ERK1 / 2 protein through the Ras / Raf / MAPK signaling pathway to transduce cell signals and participate in energy metabolism in the body. Comparing and evaluating the differences in the regulation of ERK1 / 2 protein phosphorylation levels by FGF21 protein mutants can evaluate the level of cell signal transduction.

[0199] The FGF21 protein mutant was incubated with HuH-7 liver cancer cells expressing the FGF21 receptor FGFR and the auxiliary binding protein Klotho beta. The cells were fixed and permeabilized, and then incubated with fluorescein-labeled anti-pERK1 / 2 antibodies. The intracellular signal intensity was detected by flow cytometry.

[0200] HuH-7 (Chinese Academy of Sciences, cat#: SCSP-526) was used at 1x10 5 / mL was inoculated into a 96-well plate, 100uL / well, and incubated at 37°C, 5% carbon dioxide overnight. The next day, the cells were starved for 2 hours in DMEM (gibco, cat#: 11995-065) basal medium. The test protein was diluted with DMEM basal medium in the experimental group, and the final concentration of the test protein was adjusted to 50nM, and 100uL / well was added to the plate. The control group was added with the same volume of DMEM basal medium, incubated at 37°C for 20 minutes, and fixed with fixative (BD Cytofix, cat#: 554655) at 37°C for 30 minutes, centrifuged at 400g, 4°C for 5 minutes, and washed twice. After adding permeabilization solution (BD Phosflow, cat#: 558050) at 4°C for 1 hour, Alexa 647 labeled mouse anti-human pERK1 / 2 protein antibody (Biolegend, cat#: 369504), incubated at 4°C for 1 hour, centrifuged at 400g, 4°C for 5 minutes, washed twice, 100uL / well of 2% FBS solution was added to resuspend the cells in ZE5 (Bio-Rad) flow cytometer to detect Alexa The 647 channel signal was used to calculate the pERK1 / 2 growth efficiency using the mean fluorescence intensity (MFI), and the calculation formula was: pERK1 / 2 growth rate % = (experimental group MFI-control group MFI) / control group MFI*100%. The results are shown in the following table:

[0201] Table 2 pERK1 / 2 growth rate

[0202]

[0203]

[0204] The experimental results showed that the FGF21 mutant could upregulate the phosphorylation level of ERK1 / 2 protein in HuH-7 cells at an induction concentration of 50 nM, with good results. In addition, after testing and verification, the variant protein had an isotype or allele sequence in which Leu replaced Pro at position 146 (e.g., protein number 61), which had a similar pERK1 / 2 growth rate.

[0205] Example 6 In vivo efficacy of protein No. 149

[0206] The regulatory effect of subcutaneous administration of protein No. 149 on blood glucose and body weight of db / db mice was detected and evaluated.

[0207] Male db / db mice weighing 45-55 grams and aged 10-12 weeks were purchased from Shanghai Jiesijie Experimental Animal Co., Ltd. After a single subcutaneous injection of 2 mg / kg body weight of numbered protein 149 (SEQ ID NO: 149) to db / db mice, the blood sugar and body weight of the mice were continuously observed. The specific method for measuring blood sugar levels is to fix the mice by physical methods, expose the tail and cut off a small part of the tail, squeeze the tail to make it bleed, discard the first drop of blood and use a Roche Active Blood Glucose Meter to detect blood sugar. The blood sugar levels of mice were detected at 0h, 24h, 48h, 78h, 96h, 120h, 144h and 168h. The weight of mice was measured at 0h, 24h, 48h, 78h, 96h, 120h, 144h and 168h. Through the above experimental methods, the specific data of blood sugar levels of mice are shown in the following table:

[0208] Table 3 Regulatory effects of the numbered proteins on blood glucose in db / db mice.

[0209]

[0210] Table 4 Regulatory effects of the numbered proteins on the body weight of db / db mice.

[0211]

[0212] The experimental results showed that the test protein exhibited significant and lasting hypoglycemic and weight-lowering effects, indicating that it has the potential to become a long-acting drug for regulating metabolism.

[0213] Example 7 In vivo efficacy of proteins No. 149 and 150

[0214] A high-fat diet was used to induce an obesity model in C57BL / 6 mice, namely the DIO model mice, to evaluate the effects of candidate molecules in reducing body weight, fasting blood glucose levels, liver-to-body weight ratio, and four blood lipid levels in mice: total cholesterol (TC), triglycerides (TG), high-density lipoprotein cholesterol (HDL-cholesterol, HDL-C), and low-density lipoprotein cholesterol (LDL-cholesterol, LDL-C).

[0215] DIO (Nanjing Jicui Yaokang) male obesity model mice weighing 30-50g and aged 12 weeks were randomly divided into 4 groups, with 7 animals in each group. The tested FGF21 fusion protein mutants 149 and 150 were administered with 4mpk, sc, q3d, for a total of 3 times. The body weight was weighed and the drug was administered on the 0th day. The drug was administered and the body weight was measured every 3 days thereafter, and the food intake was accumulated. The mice were weighed and fasted overnight on the 9th day. The blood was taken and the liver was taken, and the liver and body weight were weighed respectively. The blood glucose concentration at the end of the experiment was detected using a Roche blood glucose meter (vitality, GB). The four blood lipid indicators TG, TC, HDL, and LDL of the Hitachi 7060 fully automatic biochemical analyzer / Olympus AU400 fully automatic biochemical analyzer were used to calculate the liver to body weight ratio. The experimental results are shown in the following table:

[0216] Table 5 Body weight changes of DIO mice

[0217]

[0218]

[0219] Table 6 Cumulative food intake of DIO mice (g / mouse)

[0220]

[0221] Table 7 Blood glucose and liver weight ratio of mice at the end point (day 10)

[0222]

[0223] Table 8 Changes of four blood lipid indexes at the end point (day 10) of DIO mice

[0224]

[0225] The experimental results showed that as the mice's food intake increased, proteins numbered 149 and 150 showed significant and lasting hypoglycemic and weight-lowering effects; at the same time, the liver-to-body weight ratio decreased, indicating that liver fat accumulation decreased; the four blood lipid indicators TG, TC, HDL-C, and LDL-C were statistically different from those in the PBS solvent group, and the test proteins showed good metabolic regulation effects.

[0226] Example 8 PK study of proteins numbered 149 and 150

[0227] The human FcRn transgenic mouse model was used to evaluate the drug metabolism of FGF21 fusion protein mutants 149 and 150 in mice.

[0228] Human FcRn transgenic mice (Biocytogen) with an average body weight of 18-22g and an age of 18-22 weeks were randomly divided into 3 groups, with 3 animals in each group. The tested FGF21 fusion protein mutants 149 and 150 were administered in a single dose of 4mpk, sc, and PBS solvent was used as a negative control group. Blood was collected and plasma was separated at 0.5, 2, 4, 6, 8, 24, 48, 72, 96, and 120 hours after administration, and frozen in a -20°C refrigerator. The concentration of FGF21 fusion protein mutants in mouse plasma was then detected by the HTFR method using a human Fc detection kit (Cisbio, 62HFCPEG), and the PK parameters were analyzed using the non-compartmental model and intravascular administration formula of the PK solver software. The experimental results are shown in the following table:

[0229] Table 9 PK parameters of numbered proteins

[0230] Main parameters unit 149 150 <![CDATA[t 1 / 2 ]]> h 212 143.2 <![CDATA[C max ]]> ug / ml 103.4 60.4 <![CDATA[T max ]]> h 24 24 <![CDATA[AUC 0-t ]]> ug / ml*h 10415 5854.7 AUC 0-inf_obs ug / ml*h 32211.4 13180.2 MRT 0-inf_obs h 307.5 207.9 Cl_obs (mg / kg) / (ug / ml) / h 1.24E-10 3.03E-10

[0231] Integrated half-life t 1 / 2 , exposure, peak time of maximum blood drug concentration and other parameters, proteins numbered 149 and 150 both showed good in vivo metabolic activity.

[0232]

[0233]

[0234]

[0235]

[0236]

[0237]

[0238]

[0239]

[0240]

[0241]

[0242]

[0243]

[0244]

[0245]

[0246]

[0247]

Claims

1. A FGF21 protein or a variant thereof, characterized in that Selected from sequences SEQ ID NO:61, 169.

2. A fusion protein, the general formula of which is as follows: F1-F2-F3 (II) in: F1 is selected from the FGF21 protein or a variant thereof as described in claim 1; F2 is a connexin with the general formula: F4F5(GGGGS) m F5(GGGGS) n (III) wherein F4 is SEQ ID NO: 145, F5 is the Fc fragment of immunoglobulin, m=1-20, n=1-8; F3 is GDF15 protein or a variant thereof, wherein the sequence of F3 is SEQ ID NO:

148.

3. The fusion protein according to claim 2, wherein the connexin of F2 has the general formula (III), characterized in that: Among them, F5 is SEQ ID NO:

146.

4. The fusion protein according to claim 2, wherein the connexin of F2 has the general formula (III), characterized in that: Where m=10.

5. The fusion protein according to claim 2, wherein the connexin of F2 has the general formula (III), characterized in that: Where n=4. The fusion protein according to claim 2 , wherein the specific sequence of F2 is SEQ ID NO:

147.

7. The fusion protein of general formula (II) according to claim 2, wherein the specific sequences are SEQ ID NOs: 149 and 150.

8. A polynucleotide encoding the FGF21 protein or a variant thereof according to claim 1, or the fusion protein according to any one of claims 2 to 7.

9. An expression vector comprising the polynucleotide according to claim 8.

10. A host cell introduced into or containing the expression vector according to claim 9, wherein the host cell is selected from bacteria, yeast or mammalian cells.

11. The host cell according to claim 10, wherein the bacteria is selected from Escherichia coli; the yeast is selected from Pichia pastoris; and the mammalian cell is selected from CHO cells or HEK293 cells.

12. A method for producing a protein, comprising the steps of: Cultivating the host cell according to claim 10 or 11; Isolation of proteins from cultures; and purifying the protein.

13. A pharmaceutical composition comprising the FGF21 protein or variant thereof according to claim 1, or the fusion protein according to any one of claims 2 to 7, and a pharmaceutically acceptable carrier.

14. Use of the FGF21 protein or its variant according to claim 1, or the fusion protein according to any one of claims 2-7, or the pharmaceutical composition according to claim 13 in the preparation of a medicament for treating or preventing diabetes, obesity, dyslipidemia, metabolic syndrome, non-alcoholic fatty liver or non-alcoholic steatohepatitis-related diseases.